Kyprolis (Amgen/Ono Pharmaceutical) Drug Report 2017-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Kyprolis" report has been added to ResearchAndMarkets.com's offering.

Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome.

The proteasome is a cellular complex that breaks down proteins; it is believed to play a critical role in the degradation (and therefore regulation) of a number of proteins involved in the regulation of cell cycle, apoptosis, and angiogenesis. In vitro, Kyprolis has shown antiproliferative and proapoptotic activity in both solid and hematologic tumor cells. In animal studies, it was shown to inhibit proteasome activity and delay tumor growth in models of multiple myeloma, hematological malignancies, and solid tumors.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Kyprolis : Multiple myeloma
  4. Kyprolis : NHL: Mantle cell lymphoma (MCL)

List of Figures

Figure 1: Kyprolis for multiple myeloma - SWOT analysis

Figure 2: The authors drug assessment summary of Kyprolis for multiple myeloma

Figure 3: The authors drug assessment summary of Kyprolis for multiple myeloma

Figure 4: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Kyprolis for mantle cell lymphoma - SWOT analysis

List of Tables

Table 1: Kyprolis drug profile

Table 2: Kyprolis pivotal trial data in multiple myeloma

Table 3: Kyprolis late-phase trial data in multiple myeloma

Table 4: Kyprolis early-phase trial data in multiple myeloma

Table 5: Kyprolis ongoing Phase III trials in multiple myeloma

Table 6: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 7: Patients treated with Kyprolis across the US, Japan, and five major EU markets, by country, 2017-26

Table 8: Kyprolis drug profile

Table 9: Kyprolis Phase I/II trials in mantle cell lymphoma

For more information about this report visit https://www.researchandmarkets.com/r/lpkyeb

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs